Lv71
4430 积分 2022-07-29 加入
Discovery of Potent and Selective Pyrrolo[2,3-d]pyrimidine Derivatives as Fourth-Generation EGFR Inhibitors Targeting Triple Mutations
3天前
已完结
Akt Inhibitor Advancements: From Capivasertib Approval to Covalent-Allosteric Promises
13天前
已完结
Scaffold Hopping Method for Design and Development of Potential Allosteric AKT Inhibitors
13天前
已完结
Selective targeting of endothelial and perivascular angiocrine ROCK2 treats liver fibrosis
19天前
已完结
From KRAS G12D to Pan-KRAS Inhibitors─A Journey Enabled by Synthetic Innovation and Structure-Based Drug Design
22天前
已完结
Discovery of FLC-8 as the First Covalent FLT3 Inhibitor Targeting Cys807 for FLT3 Mutant Acute Myeloid Leukemia
28天前
已完结
Discovery of a Novel Potent EGFR Inhibitor Against EGFR Activating Mutations and On-Target Resistance in NSCLC
1个月前
已完结
PROTAC approaches against drug-resistant EGFRC797S/L858R/T790M mutants: biological evaluation and SAR studies (2020–2025)
1个月前
已完结
HBE‐843, a Novel, Potent, and Selective EGFR Targeting PROTAC for the Treatment of Non‐Small‐Cell Lung Cancer
1个月前
已完结
The next generation of EGFR inhibitors: a patenting perspective of PROTACs based EGFR degraders
1个月前
已完结
皖公网安备34019202002308
